With the results of the primary analysis of monarchE, abemaciclib was first approved for the adjuvant treatment of early-stage breast cancer in October 2021, with the population limited to those with Ki-67 ≥ 20% in Cohort 1 [99]. Here, MKI67 is linked to breast carcinoma.